



October 29, 2009

Company Name: Dainippon Sumitomo Pharma Co., Ltd.
 Representative: Masayo Tada, President
 (Securities Code: 4506, 1st Section of TSE and OSE)

Difference from Financial Forecasts for the Second Quarter of the Year Ending March 31, 2010 and Revision of Financial Forecasts for the Year Ending March 31, 2010

Dainippon Sumitomo Pharma Co., Ltd. announced the difference between financial results and forecasts for the second quarter of the year ending March 31, 2010.
 In addition, the revision of financial forecasts for the year ending March 31, 2010 was announced.

(millions of yen)

1. Difference from Consolidated Financial Forecasts for the Second Quarter of the Year Ending March 31, 2010 (April 1, 2009 to September 30, 2009)

	Net sales	Operating income	Ordinary income	Net income	Earnings per share (yen)
Previous forecasts (A)	130,600	12,800	12,400	7,800	¥19.63
Results (B)	132,210	18,919	19,053	12,654	¥31.85
(B – A)	1,610	6,119	6,653	4,854	
Change (%)	1.2	47.8	53.7	62.2	
(Reference) Results for the six months ended September 30, 2008	134,358	18,177	18,208	10,870	¥27.35

2. Revision of Consolidated Financial Forecasts for the Year Ending March 31, 2010 (April 1, 2009 to March 31, 2010)

	Net sales	Operating income	Ordinary income	Net income	Earnings per share (yen)
Previous forecasts (A)	264,000	25,000	24,000	15,000	¥37.75
New forecasts (B)	264,000	29,000	27,000	18,000	¥45.30
(B – A)	0	4,000	3,000	3,000	
Change (%)	0.0	16.0	12.5	20.0	
(Reference) Results for the year ended March 31, 2009	264,037	31,166	31,395	19,987	¥50.30

3. Difference from Non-Consolidated Financial Forecasts for the Second Quarter of the Year Ending March 31, 2010 (April 1, 2009 to September 30, 2009)

	Net sales	Operating income	Ordinary income	Net income	Earnings per share (yen)
Previous forecasts (A)	121,600	12,800	12,500	7,700	¥19.38
Results (B)	123,833	18,161	18,310	11,920	¥30.00
(B – A)	2,233	5,361	5,810	4,220	
Change (%)	1.8	41.9	46.5	54.8	
(Reference) Results for the six months ended September 30, 2008	126,187	18,052	18,126	10,929	¥27.50

4. Revision of Non-Consolidated Financial Forecasts for the Year Ending March 31, 2010
(April 1, 2009 to March 31, 2010)

	Net sales	Operating income	Ordinary income	Net income	Earnings per share (yen)
Previous forecasts (A)	245,000	23,900	23,000	14,100	¥35.49
New forecasts (B)	245,000	27,300	25,400	16,500	¥41.53
(B – A)	0	3,400	2,400	2,400	
Change (%)	0.0	14.2	10.4	17.0	
(Reference) Results for the year ended March 31, 2009	248,433	30,582	30,893	19,729	¥49.65

5. Reason for Difference and Revision

< Net sales >

Actual sales until the end of the second quarter have been nearly in line with the previous forecasts. Accordingly, the previous forecasts for the full year have been unchanged.

< Operating income >

One of the Company's focused challenges in the year ending March 31, 2010 is to strive for efficient management and for efficient and profitable corporate structure. All the expenses are reexamined for the necessity and R&D expenses are spent efficiently based on prioritization. Owing to these efforts, coupled with the carry-over of R&D expenses and other expenses to the third quarter or later, actual operating income for the second quarter increased compared to the previous forecasts.

As to the full year, owing to efforts for the improvement in management efficiency and for the efficient and profitable corporate structure, the Company anticipates selling, general and administrative expenses, manufacturing costs and others to be reduced more than expected. Accordingly, the Company now forecasts increase in operating income by ¥4.0 billion compared to the previous forecasts.

< Ordinary income / Net income >

Although non-operating expenses such as interest expense are expected to increase due mainly to financing for the acquisition of Sepracor Inc., the Company now forecasts increase in ordinary income as well as net income by ¥3.0 billion compared to the previous forecasts.

It should be noted that the above forecasts do not include any performance figures of Sepracor Inc., which has recently become an indirect wholly-owned subsidiary of the Company. Goodwill and in-process R&D, etc. resulting from the acquisition are under evaluation at present, and their financial impact will be announced once determined.

Note: Forecasts shown above are based on management's assumptions and beliefs in light of the information currently available, and involve risks and uncertainties. Actual financial results may differ materially depending on a number of factors, including economic conditions.